JennyCChangMD

Breast Cancer, Hematologic Oncology

Professor of Medicine, Weill Cornell Medical School, Director Houston Methodist Cancer Center

Telehealth Available

Overview of Dr. Chang

Dr. Jenny Chang is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, Houston Methodist Clear Lake Hospital, and St. Luke's Health - Baylor St. Luke's Medical Center. She received her medical degree from University of Cambridge School of Medicine and has been in practice 28 years. Dr. Chang accepts several types of health insurance, listed below. She is one of 90 doctors at Houston Methodist Hospital and one of 97 doctors at St. Luke's Health - Baylor St. Luke's Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
6550 Fannin St
Ste 1101
Houston, TX 77030
Book by Phone+1(346) 594-5187

Fax+1 713-790-2797

Education & Training

University of Cambridge School of MedicineClass of 1989

Certifications & Licensure

TX State Medical License 2002 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2006-2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer Start of enrollment: 2010 Jun 01
Unknown status
Phase 1
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Olive Oil for High Risk Breast Cancer Prevention in Women Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
Emotions Immunology and Breast Cancer Start of enrollment: 2015 Nov 23
Completed
Not Applicable
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer Start of enrollment: 2021 Mar 17
Suspended
Phase 2
Combined Immunotherapies in Metastatic ER+ Breast Cancer Start of enrollment: 2020 Nov 12
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

MnSOD non-acetylation mimic knock-in mice exhibit dilated cardiomyopathy.
Joseph R Schell, Sung-Jen Wei, Jun Zhang, Rolando Trevino Jr, Wan Hsi Chen
Free Radical Biology & Medicine. 2025-03-01
Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer.
Akshjot Puri, Zheng Yin, Sergio Granados-Principal, Joe Ensor, Liliana Guzman
International Journal of Breast Cancer. 2025-01-01
Interplay Between Residential Nature Exposure and Walkability and Their Association with Cardiovascular Health.
Omar M Makram, Nwabunie Nwana, Alan Pan, Juan C Nicolas, Rakesh Gullapelli
JACC. Advances. 2025-01-01

Journal Articles

Hydroxytyrosol Inhibits Cancer Stem Cells and the Metastatic Capacity of Triple-Negative Breast Cancer Cell Lines by the Simultaneous Targeting of Epithelial-to-Mesenc...
Anthony M Brown, Jenny C Chang, European Journal of Nutrition

Press Mentions

Drug Combination Identified That Combats Aggressive Form of Breast CancerFebruary 3rd, 2025
Houston Methodist Researchers Pioneer New Treatment Strategies for Metaplastic Breast CancerJanuary 22nd, 2025
Houston Hospital Names Leading Cancer Scientist as New Academic HeadJanuary 21st, 2025
Join now to see all

Grant Support

Treatment Resistance Pathways &Targeting Residula CancersNational Cancer Institute2008–2012
Targeting Notch, PI3K-AKT And Other Novel Pathways In Breast Cancer Stem CellsNational Cancer Institute2011
Targeting Notch, PI3K-AKT And Other Novel Pathways In Breast Cancer Stem CellsNational Cancer Institute2008–2010
NSABP Participating SitesNational Cancer Institute2007–2009
Breast Cancer Response Markers To A Dual Her1/2 BlockerNational Cancer Institute2005–2009
Mechanism Of Action Of Herceptin R In Breast CancerNational Cancer Institute2000–2002

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Texas BlueChoice
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
GHI PPO
Great West PPO
Health Net California Large Group PPO
Healthfirst New York
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment